<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676180</url>
  </required_header>
  <id_info>
    <org_study_id>15/0883</org_study_id>
    <nct_id>NCT02676180</nct_id>
  </id_info>
  <brief_title>Detecting Bladder Cancer Using the UroMark Test.</brief_title>
  <acronym>DETECT I</acronym>
  <official_title>A Prospective Observational Study to Determine the Negative Predictive Value of UroMark to Rule Out the Presence of Bladder Cancer in Patients With Haematuria.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DETECT I is a prospective multicentre observational diagnostic study to assess the
      performance of the UroMark assay to rule out bladder cancer in patients with haematuria. The
      study will recruit consecutive patients attending haematuria clinics as well as patients
      referred to urology outpatient clinics for investigation of haematuria. Consenting patients
      will be provided with a urine sample collection kit and asked to provide a urine sample. An
      additional urine sample for control assay testing will be provided after the clinic
      attendance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transitional cell carcinoma (TCC) of the urinary bladder is responsible for &gt;12,000 new cases
      of cancer and &gt;5,000 deaths per year in England and Wales. Most bladder cancers are
      non-muscle invasive bladder cancer (NMIBC) and do not invade deeply at presentation, but 80%
      of tumours recur within 3 years. For muscle invasive bladder cancer (MIBC), the 5 year
      survival is around 50%. Cystoscopy is the standard test for detection of bladder cancer along
      with imaging to assess the upper tracts and the common presenting symptom is haematuria.
      Cystoscopy is an invasive procedure and results in urinary infection in up to 5% of cases.
      Cystoscopy is performed under local anaesthetic and patients are required to attend hospital
      clinics for the test. About one in 10 patients who are investigated for haematuria will be
      found to have bladder cancer. Frequently, patients are not referred for investigation of
      haematuria at the time of first presentation and there is a delay in diagnosis of the
      disease. The early detection of bladder cancer by means of a non-invasive tumour marker test
      would impact on the management of the disease. There is an unmet need for a simple,
      non-invasive, highly sensitive and specific method for detecting bladder cancer.

      This study will determine the accuracy of UroMark a high-throughput multiplex PCR test to
      detect bladder cancer in DNA from urine. The study will address the unmet clinical need to
      improve detection of bladder cancer. The rationale for the trial is based on proof of concept
      studies which provide compelling evidence that a panel of methylation markers can be applied
      to detect bladder cancer with high sensitivity and specificity. It will be also be possible
      to collect and store fractions of urine for assessment of other DNA related biomarkers as
      well as non-DNA assays for example cellular proteins, soluble biomarkers in urine supernatant
      and RNA transcripts in sediment cells. In this study we will compare the UroMark assay with
      established assays including urinary cytology, FISH as well as developing assays such as
      MCM5. In this proposal excess urine will be stored for these studies.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Negative predictive value (NPV) of the UroMark test.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value (NPV) of control assay (FDA approved urinary marker (UroVision)).</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value (NPV) against imaging (ultrasound/CT)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value (NPV) against combination of UroMark and imaging.</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">3700</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group</intervention_name>
    <other_name>Observational</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine will be collected for analysis using UroMark assay.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with visible and non-visible haematuria (blood in urine) will be enrolled. About
        10% of cases with haematuria will be found to have bladder cancer. For the majority of
        cases (60.5%), no cause is found. Other causes include stone disease (3.6%), benign
        prostate conditions (20-30%), renal disease (9.8%) infection (13%) and renal/prostate
        cancer (1%). The DETECT I study will determine if the UroMark test can be used to rule out
        bladder cancer in cases referred for investigation of haematuria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be over 18 years of age.

          -  Participants undergoing investigation for visible and non-visible haematuria.

          -  Able to give informed written consent.

        Exclusion Criteria:

          -  Unwilling to have standard haematuria investigations.

          -  Unable to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kelly, FRCS (urol)</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLH</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.</citation>
    <PMID>23295957</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586.</citation>
    <PMID>23303884</PMID>
  </reference>
  <reference>
    <citation>Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009 Aug;56(2):247-56. doi: 10.1016/j.eururo.2009.04.038. Epub 2009 Apr 24.</citation>
    <PMID>19409692</PMID>
  </reference>
  <reference>
    <citation>Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP. Gender inequalities in the promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence from secondary analysis of an English primary care audit survey. BMJ Open. 2013 Jun 24;3(6). pii: e002861. doi: 10.1136/bmjopen-2013-002861.</citation>
    <PMID>23798742</PMID>
  </reference>
  <reference>
    <citation>Mitra AP, Cote RJ. Molecular screening for bladder cancer: progress and potential. Nat Rev Urol. 2010 Jan;7(1):11-20. doi: 10.1038/nrurol.2009.236. Review.</citation>
    <PMID>20062071</PMID>
  </reference>
  <reference>
    <citation>Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU Int. 2005 Jan;95(1):59-63.</citation>
    <PMID>15638895</PMID>
  </reference>
  <reference>
    <citation>Rodgers M, Nixon J, Hempel S, Aho T, Kelly J, Neal D, Duffy S, Ritchie G, Kleijnen J, Westwood M. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess. 2006 Jun;10(18):iii-iv, xi-259. Review.</citation>
    <PMID>16729917</PMID>
  </reference>
  <reference>
    <citation>Kelly JD, Fawcett DP, Goldberg LC. Assessment and management of non-visible haematuria in primary care. BMJ. 2009 Jan 16;338:a3021. doi: 10.1136/bmj.a3021. Review.</citation>
    <PMID>19151065</PMID>
  </reference>
  <reference>
    <citation>Mowatt G, N'Dow J, Vale L, Nabi G, Boachie C, Cook JA, Fraser C, Griffiths TR; Aberdeen Technology Assessment Review (TAR) Group. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care. 2011 Jan;27(1):3-10. doi: 10.1017/S0266462310001364. Epub 2011 Jan 25. Review.</citation>
    <PMID>21262078</PMID>
  </reference>
  <reference>
    <citation>Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000 Feb;163(2):524-7.</citation>
    <PMID>10647670</PMID>
  </reference>
  <reference>
    <citation>Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int. 2006 Feb;97(2):301-5; discussion 305.</citation>
    <PMID>16430634</PMID>
  </reference>
  <reference>
    <citation>Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, Sagalowsky AI. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol. 2009 Jul;182(1):52-7; discussion 58. doi: 10.1016/j.juro.2009.02.142. Epub 2009 May 17.</citation>
    <PMID>19450825</PMID>
  </reference>
  <reference>
    <citation>Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, Westra WH, Schoenberg M, Zahurak M, Goodman SN, Sidransky D. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst. 2006 Jul 19;98(14):996-1004.</citation>
    <PMID>16849682</PMID>
  </reference>
  <reference>
    <citation>Dudderidge TJ, Kelly JD, Wollenschlaeger A, Okoturo O, Prevost T, Robson W, Leung HY, Williams GH, Stoeber K. Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments. Br J Cancer. 2010 Aug 24;103(5):701-7. doi: 10.1038/sj.bjc.6605785. Epub 2010 Jul 20.</citation>
    <PMID>20648010</PMID>
  </reference>
  <reference>
    <citation>Coenen MJ, Ploeg M, Schijvenaars MM, Cornel EB, Karthaus HF, Scheffer H, Witjes JA, Franke B, Kiemeney LA. Allelic imbalance analysis using a single-nucleotide polymorphism microarray for the detection of bladder cancer recurrence. Clin Cancer Res. 2008 Dec 15;14(24):8198-204. doi: 10.1158/1078-0432.CCR-08-1103.</citation>
    <PMID>19088036</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

